Muted activity in the private equity (“PE”) deal environment in the first and second quarters of 2024 continues to reflect ongoing challenges in the market. Rosy projections voiced at the McDermott Will & Emery HPE Conference have yet to materialize, as evidenced by the modest decline in deal volume announced in May 2024. However, this trend is likely to change as we progress through 2024, driven by PE deal pipelines with strategic targets, sector-specific opportunities, and a focus on value creation. Smaller and less-frequent deals with longer conversation timelines will continue to represent most of the deal activity.
Read the full article: Healthcare and Life Sciences M&A Outlook //
Source: https://www.lexology.com/library/detail.aspx?g=5f6ae75a-1dd1-4fdb-9bd2-cd6cd3c440e0